Global single-cell sequencing market projected to reach $7,420.8 million by 2032, driven by demand for personalized therapies.

From GlobeNewswire: 2025-06-11 09:50:00

The global Single-Cell Sequencing Market was valued at USD 2,109.8 million in 2023 and is projected to reach USD 7,420.8 million by 2032, with a CAGR of 15%. The rising trend in single-cell technology is driven by demand for personalized therapies in cancer and immunology studies, and multi-omic strategies for cellular diversity.

The U.S. market alone was worth USD 590.15 million in 2023, projected to reach USD 1,925.10 million by 2032. North America is expected to lead in single-cell innovation due to rapid adoption of sequencing platforms, data analytics, and integration of AI in genomics.

Next Generation Sequencing (NGS) dominates the market, accounting for 45% in 2023. Single-molecule real-time sequencing is experiencing rapid growth due to its epigenetic capabilities and long-read feature for complex genome mapping. Cancer research leads applications, accounting for 36% in 2023.

Academic and research institutions held the largest market share of 74% in 2023, while biotechnology and pharmaceutical companies are expanding at the highest CAGR. North America dominates the market, with Europe maintaining a significant position and Asia-Pacific witnessing the fastest growth.

Recent developments include new kits from 10x Genomics and Parse for single-cell analysis, as well as updates from Mission Bio for simultaneous DNA and protein analysis at the single-cell level.

SNS Insider is a leading market research and consulting agency providing clients with current, accurate market data, consumer insights, and opinions to make confident decisions in a changing market landscape.



Read more at GlobeNewswire: Single-Cell Sequencing Market to Hit USD 7,420.8 Million by